By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion Pharmaceuticals Inc.  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
As AbbVie (ABBV) Eyes Alzheimer's Franchise, Speculation Mounts About a $4.5B Marriage to Acadia (ACAD) 4/8/2015 8:54:02 AM
Acadia (ACAD) To Present At The 14th Annual Needham Healthcare Conference On April 14, 2015 4/7/2015 10:57:23 AM
Acadia (ACAD) Appoints Daniel Soland To Board Of Directors 3/26/2015 8:40:19 AM
Acadia (ACAD) Updates Planned Timing Of NUPLAZID NDA Submission 3/12/2015 7:51:00 AM
Acadia (ACAD) Tanks as Key Drug is Delayed, CEO Resigns 3/12/2015 6:02:37 AM
Acadia (ACAD) Stock Hits All-Time High as Canceled Meetings Spur M&A Rumors 3/10/2015 2:42:59 PM
ACADIA Pharmaceuticals, Inc. (ACAD) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 2/27/2015 10:46:19 AM
ACADIA Pharmaceuticals, Inc. (ACAD) To Present At Upcoming Investor Conferences 2/24/2015 11:13:49 AM
ACADIA Pharmaceuticals, Inc. (ACAD) To Announce Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015 2/19/2015 12:34:48 PM
ACADIA Pharmaceuticals, Inc. (ACAD) Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson’s Disease And Related Disorders 12/8/2014 10:45:23 AM